Novavax(NVAX) ZACKS·2025-02-20 23:50Company Performance - Novavax (NVAX) closed at 0.67, which represents a 53.47% increase compared to the same quarter last year [2] - Revenue is projected to be $90.72 million, indicating a significant decline of 68.86% from the equivalent quarter last year [2] Analyst Estimates - Recent changes in analyst estimates for Novavax reflect shifting short-term business dynamics, with positive revisions indicating optimism about the company's profitability [3] - The Zacks Rank system, which incorporates these estimate changes, provides actionable ratings for investors [4] Zacks Rank and Performance - Novavax currently holds a Zacks Rank of 2 (Buy), with the consensus EPS estimate having increased by 2899.99% over the past month [5] - Historically, stocks rated 1 (Strong Buy) have delivered an average annual return of +25% since 1988 [5] Valuation Metrics - Novavax has a Forward P/E ratio of 100.25, which is significantly higher than the industry's average Forward P/E of 23.12 [6] - The company has a PEG ratio of 2.88, compared to the average PEG ratio of 1.67 for Medical - Biomedical and Genetics stocks [7] Industry Context - The Medical - Biomedical and Genetics industry is part of the Medical sector and currently holds a Zacks Industry Rank of 67, placing it in the top 27% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]